Patton Albertson Miller Group LLC Raises Stock Position in Danaher Corporation $DHR

Key Points

• Patton Albertson Miller Group LLC increased its stake in Danaher Corporation by 5.0%, holding 36,294 shares valued at $7.17 million, making it the fund's 28th largest holding.
• Danaher recently reported quarterly earnings of $1.80 per share, surpassing analysts' expectations, with a revenue of $5.94 billion, reflecting a year-over-year growth of 3.4%.
• The company announced a quarterly dividend of $0.32, payable on October 31st, which represents an annualized yield of 0.7% and a payout ratio of 27.23%.

Patton Albertson Miller Group LLC boosted its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 5.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,294 shares of the conglomerate's stock after purchasing an additional 1,731 shares during the quarter. Danaher comprises 0.9% of Patton Albertson Miller Group LLC's investment portfolio, making the stock its 28th largest holding. Patton Albertson Miller Group LLC's holdings in Danaher were worth $7,169,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of DHR. GAMMA Investing LLC raised its position in Danaher by 24,958.2% in the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock valued at $383,524,000 after purchasing an additional 1,863,381 shares during the last quarter. Summit Global Investments raised its position in Danaher by 18.0% in the 1st quarter. Summit Global Investments now owns 1,057 shares of the conglomerate's stock valued at $217,000 after purchasing an additional 161 shares during the last quarter. Parallel Advisors LLC increased its stake in Danaher by 37.7% in the 1st quarter. Parallel Advisors LLC now owns 17,409 shares of the conglomerate's stock valued at $3,569,000 after buying an additional 4,763 shares during the period. Global Financial Private Client LLC increased its stake in Danaher by 18.9% in the 1st quarter. Global Financial Private Client LLC now owns 1,134 shares of the conglomerate's stock valued at $232,000 after buying an additional 180 shares during the period. Finally, Burns J W & Co. Inc. NY increased its stake in Danaher by 1.8% in the 1st quarter. Burns J W & Co. Inc. NY now owns 39,803 shares of the conglomerate's stock valued at $8,160,000 after buying an additional 718 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on DHR. Guggenheim reissued a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research note on Tuesday, September 2nd. Robert W. Baird boosted their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Bank of America lowered their price target on shares of Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a research note on Monday, September 22nd. Finally, UBS Group lowered their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $245.91.

Danaher Price Performance

Shares of NYSE DHR opened at $184.97 on Friday. The stock has a market cap of $132.45 billion, a price-to-earnings ratio of 39.36, a PEG ratio of 2.63 and a beta of 0.75. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.59. The company's 50-day moving average price is $199.44 and its 200 day moving average price is $197.53. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is 27.23%.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.